Clinical trials
Acute Promyelocytic Leukemia clinical trials
Below are recruiting acute promyelocytic leukemia clinical trials, each written for real people, not researchers. We’re tracking 244 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06549790RecruitingPhase 1
Study of NMS-03597812 for relapsed or refractory AML
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT05924750RecruitingPhase 1
Testing a CD33-targeted drug for difficult AML
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
Hefei, AnhuiAges 18–75 - NCT06191978RecruitingPhase 1
Testing venetoclax with decitabine/cedazuridine for pediatric AML
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
Houston, TexasAges 2–18 - NCT05627232RecruitingPhase 1
Tazemetostat and palbociclib for relapsed or resistant AML
This early-phase study tests whether tazemetostat and palbociclib can help people with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It looks for safety and early signs of how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05580601RecruitingPhase 1/Phase 2
Immunotherapy trial for children with relapsed or stubborn AML
This Phase 1/2 trial tests a lab-made immune-cell treatment (NK cells) for children with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It aims to help the immune system attack leukemia cells in the bone marrow, especially when standard treatments have not worked.
Cincinnati, OhioAges 2 years+ - NCT05183035RecruitingPhase 3
Testing venetoclax for children with relapsed AML
This study tests a drug called venetoclax in children and young adults whose acute myeloid leukemia (AML) has returned after treatment. The drug may help block cancer cell growth. The study also looks at safety and how well the drug works when given alone or with other treatments.
Phoenix, ArizonaAges 4 weeks–21 years - NCT05603884RecruitingPhase 2
New treatment plan for older adults with newly diagnosed AML
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Xiamen, FujianAges 60 years+ - NCT06852222RecruitingPhase 3
Study of bleximenib, venetoclax, and azacitidine for newly diagnosed AML
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Birmingham, AlabamaAges 18 years+ - NCT07503730RecruitingPhase 3
Early use of realgar-indigo naturalis formula plus ATRA for APL patients
This trial tests whether giving a combination of two oral medicines—realgar-indigo naturalis formula (RIF) and all-trans retinoic acid (ATRA)—early in treatment can help people with acute promyelocytic leukemia (APL), a specific type of blood cancer. The goal is to see if this approach works better than current standard care.
Xi'an, ShaanxiAges 18–80 - NCT05881265RecruitingPhase 2
Chidamide plus venetoclax for hard-to-treat APL
This trial studies chidamide and venetoclax in people with a specific type of acute promyelocytic leukemia (APL) that has not responded to standard treatment with all-trans retinoic acid (RA) plus arsenic. It may help by testing a new combination for cases in “non-remission” status.
Huai'an, JiangsuAges 16–70 - NCT07867600Recruiting
Lower-dose chemo for children with new leukemia
This trial tests a lower starting dose of chemotherapy for children newly diagnosed with acute myeloid leukemia (AML), a type of blood cancer. The goal is to see if a reduced dose is still effective and safer for children.
Asyut, Asyut GovernorateAges Up to 18 years - NCT06394011RecruitingPhase 2
New drug combo for intermediate/high risk AML
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Suzhou, JiangsuAges 18–65 - NCT07616089RecruitingPhase 1
Study of a new pill for advanced blood cancers
This trial tests a new pill for people with certain blood cancers that have not gotten better with standard treatments. It aims to see if the drug is safe and works, and it may help shrink tumors or slow the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06045819Recruiting
Predicting venetoclax response in newly diagnosed AML patients
This study looks at how blood levels of the drug venetoclax relate to remission in adults with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. It aims to help doctors dose the drug more effectively.
CaenAges 60–90 - NCT07108530RecruitingPhase 2
Chemotherapy and transplant for adult acute myeloid leukemia
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
Taiyuan, ShanxiAges 14–65 - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT05949125RecruitingPhase 1
Immune cell therapy for advanced acute myeloid leukemia
This trial tests a new type of immune cell therapy (called Allo-RevCAR01-T cells) for people with relapsed or hard-to-treat acute myeloid leukemia (AML) that has a marker called CD123. The treatment is given with a separate molecule that helps activate these cells to attack the leukemia. The goal is to see if this approach is safe and can help control the disease.
Ulm, Baden-WurttembergAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05010772RecruitingPhase 1
Maintenance treatment study for AML in remission
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT04897490Recruiting
Real-world study of ATO plus ATRA for adult acute APL
This study looks at how well first-time treatment with ATO plus ATRA works in adults with acute promyelocytic leukemia (APL). It mainly checks treatment results in real life, including whether patients reach “molecular remission” (very deep disease control).
La Plata, Buenos AiresAges 18 years+ - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT06329999Recruiting
CMGV for recurrent AML and high-risk MDS
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06418776RecruitingPhase 3
Comparing treatments for AML that returns or doesn't respond
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
MoscowAges 18 years+ - NCT07783100RecruitingPhase 2
Combination treatment for relapsed or refractory acute myeloid leukemia
This study tests a combination of three drugs (venetoclax, chidamide, and chiglitazar) for people with acute myeloid leukemia (AML) that has not responded to standard treatment or has returned. The goal is to see if this combination can help control the leukemia and is safe.
Xiamen, FujianAges 18 years+
Hear when a new Acute Promyelocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute promyelocytic leukemia?
- Yes. Clin2 currently lists 244 recruiting acute promyelocytic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute promyelocytic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute promyelocytic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.